Chart - you can draw at the chart
Starting Amount
Dividend yield
Dividends reinvested
MAKO Surgical Corp.
Industry Medical devices
Fate Acquired by Stryker Corporation
Founded 2004
Founder Rony Abovitz, Maurice Ferre, M.D.
Defunct December 17, 2013 (2013-12-17)
Key people
Maurice Ferre, Fritz LaPorte, former CFO, Treasurer, Sr. VP of Finance
  • RIO Robotic Arm Interactive Orthopedic Systems
  • RESTORIS Implants for partial knee and total hip arthroplasty
Revenue Increase US$ 102.72Million (2012)
Net income
Increase US$ -32.55Million (2012)

MAKO Surgical Corp. was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013.

Founded in 2004, the company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO (Robotic Arm Interactive Orthopedic System) as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications. The company has won numerous awards, including being named the fastest growing technology company in 2011 on Deloitte’s Technology Fast 500. Before it was purchased, it was publicly traded on the NASDAQ under stock symbol “MAKO.”

MAKO Surgical was founded in 2004 by Rony Abovitz, Maurice Ferre M.D., and other key members of its predecessor, Z-KAT, Inc. (founded in 1997 by Rony Abovitz, William Tapia, Michael Peshkin Ph.D., Julio Santos-Munne, and Wayne J. Kerness, M.D.) Z-KAT, Inc. was developing a novel haptic robotic system for medical applications, amongst a wide variety of computer-assisted surgery technologies. Z-KAT's initial haptic robotic arm technology, known as the Whole Arm Manipulator (or WAM Arm) was originally developed at MIT and then at Barrett Technology. Z-KAT's core technology team had adapted the WAM Arm for use as a testbed for surgical procedures. The initial success of the internal tests led to the development of a business plan to focus exclusively on the idea of haptic robotic technology in orthopedic surgery. MAKO's original technical team (Rony Abovitz, Arthur Quaid Ph.D., Hyosig Kang Ph.D., Lou Arata, Ph.D., and others) demonstrated a number of breakthroughs in robotics and controls, enabling a haptic robotic system (6dof) to perform accurate bone shaping through minimally invasive incisions (knee and hip).

MAKO's first MAKOplasty Partial Knee Replacement Procedure was performed in June 2006 by Martin Roche M.D. and the company went public on the NASDAQ with their IPO in February 2008. The company's first MAKOplasty Total Hip Arthroplasty (THA) procedure was performed in October 2010. The company reached milestones with the 500th MAKOplasty procedure performed in 2008, the 1000th by 2009, and more than 23,000 by 2012.

MAKO Surgical Corp. markets the RIO Robotic Arm Interactive Orthopedic System and RESTORIS Family of Implants for partial knee and total hip arthroplasty known as MAKOplasty. MAKOplasty increases accuracy in aligning and placing implants. The RIO system assists surgeons by creating a 3-D model of the patients' anatomy, enabling surgeons to develop a pre-surgical plan that customizes implant size, positioning and alignment specifically for each patient. During the procedure, real-time visual, tactile, and auditory feedback enforces a safety-zone and facilitates ideal implant positioning and placement, which reduces potential for complications.

MAKOplasty is offered in over 150 hospitals such as Jordan Hospital in Massachusetts, Mercy Medical Center in Baltimore, Maryland, Quincy Medical Center in Massachusetts, Hospital for Special Surgery in New York, and the Mayo Clinic Hospital in Jacksonville, Florida.

Investment goal date:
Dividends reinvested
MAKO Surgical Corp. MAKO report
Adjusted Actuals EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
Skyline Venture Partners V LP
4.3600% (2245249)
% ()